Strongbridge And Recorlev In Endogenous Cushing's Syndrome: Potential Impact On Liver Steatosis Seeking Alpha, 12 Jun 2019 Summary Strongbridge Biopharma has a promising clinical pipeline for the metabolic disease Cushing’s syndrome.